Evidence map›Paper›PMID 27821547›Full record

ArticleMolecular pharmacology2017

Endosomal Phosphatidylinositol 3-Kinase Is Essential for Canonical GPCR Signaling.

Yasunori Uchida, Florentine U Rutaganira, Damien Jullié, Kevan M Shokat, Mark von Zastrow

Open access · bronzeAbstract read
In one paragraph

Article in Molecular pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Role of the Purinergic P2Y2 Receptor in Pulmonary Hypertension.International journal of environmental research and public health · 2021
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yasunori UchidaDepartment of Psychiatry (Y.U., D.J., and M.Z.), Department of Cellular and Molecular Pharmacology (F.U.R., K.M.S., and M.Z.), and Howard Hughes Medical Institute (F.U.R. and K.M.S.), University of California, San Francisco, San Francisco, California uchida@med.kobe-u.ac.jp mark.vonzastrow@ucsf.edu.
Florentine U RutaganiraDepartment of Psychiatry (Y.U., D.J., and M.Z.), Department of Cellular and Molecular Pharmacology (F.U.R., K.M.S., and M.Z.), and Howard Hughes Medical Institute (F.U.R. and K.M.S.), University of California, San Francisco, San Francisco, California.
Damien JulliéDepartment of Psychiatry (Y.U., D.J., and M.Z.), Department of Cellular and Molecular Pharmacology (F.U.R., K.M.S., and M.Z.), and Howard Hughes Medical Institute (F.U.R. and K.M.S.), University of California, San Francisco, San Francisco, California.
Kevan M ShokatDepartment of Psychiatry (Y.U., D.J., and M.Z.), Department of Cellular and Molecular Pharmacology (F.U.R., K.M.S., and M.Z.), and Howard Hughes Medical Institute (F.U.R. and K.M.S.), University of California, San Francisco, San Francisco, California.
Mark von ZastrowDepartment of Psychiatry (Y.U., D.J., and M.Z.), Department of Cellular and Molecular Pharmacology (F.U.R., K.M.S., and M.Z.), and Howard Hughes Medical Institute (F.U.R. and K.M.S.), University of California, San Francisco, San Francisco, California uchida@med.kobe-u.ac.jp mark.vonzastrow@ucsf.edu.
Howard Hughes Medical Institute · USUniversity of California, San Francisco · US

Funding

The Presynaptic Vesicle Cycle for the Slow Acting Neurotransmitter SecretionP01DA010154 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KREITZER, ANATOL, SULZER, DAVID · 1995 to 2016
$14.7M
PROTEINS REGULATING ENDOCYTOSIS OF OPIOID RECEPTORSR01DA012864 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mark E Von Zastrow · 2000 to 2026
$7.9M
RESEARCH TRAINING IN CHEMISTRY AND CHEMICAL BIOLOGYT32GM064337 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT · 2002 to 2021
$7.8M
The PIP2-virus interface and PI 4-kinase: novel biology and validation targetsR01AI099245 · NIAID · STANFORD UNIVERSITY · PI GLENN, JEFFREY S · 2012 to 2016
$5.2M
Membrane Trafficking of Opioid and Adrenergic ReceptorsR01DA010711 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VONZASTROW, MARK E · 2014 to 2023
$4.6M
MEMBRANE TRAFFICKING OF OPIOID RECEPTORSR37DA010711 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VONZASTROW, MARK E · 2004 to 2013
$3.1M
MEMBRANE TRAFFICKING OF OPIOID RECEPTORSR29DA010711 · NIDA · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI VON ZASTROW, MARK E. · 1997 to 2003
$413k
NIAID NIH HHS R01 AI099245NIDA NIH HHS P01 DA010154NIDA NIH HHS R01 DA010711NIDA NIH HHS R01 DA012864NIDA NIH HHS R29 DA010711NIDA NIH HHS R37 DA010711NIGMS NIH HHS T32 GM064337
6 · The paper itself

Abstract

G protein-coupled receptors (GPCRs), the largest family of signaling receptors, are critically regulated by endosomal trafficking, suggesting that endosomes might provide new strategies for manipulating GPCR signaling. Here we test this hypothesis by focusing on class III phosphatidylinositol 3-kinase (Vps34), which is an essential regulator of endosomal trafficking. We verify that Vps34 is required for recycling of the β2-adrenoceptor (β2AR), a prototypical GPCR, and then investigate the effects of Vps34 inhibition on the canonical cAMP response elicited by β2AR activation. Vps34 inhibition impairs the ability of cells to recover this response after prolonged activation, which is in accord with the established role of recycling in GPCR resensitization. In addition, Vps34 inhibition also attenuates the short-term cAMP response, and its effect begins several minutes after initial agonist application. These results establish Vps34 as an essential determinant of both short-term and long-term canonical GPCR signaling, and support the potential utility of the endosomal system as a druggable target for signaling.

Indexed as

Signal TransductionClass III Phosphatidylinositol 3-KinasesCyclic AMPEndosomesHEK293 CellsHumansModels, BiologicalPhosphatidylinositol PhosphatesReceptors, Adrenergic, beta-2Class III Phosphatidylinositol 3-KinasesCyclic AMPphosphatidylinositol 3-phosphatePhosphatidylinositol PhosphatesReceptors, Adrenergic, beta-2

Identifiers

PMID27821547
PMCPMC5198513
OpenAlexW2556858126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.